Q3 2025 Holdings
Filed 2025-11-14 | 152 holdings | $6.6B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Nuvalent Inc(NUVL) | COM | 670703107 | $1.6B | 17,991,024 | 23.8% |
| Centene Corp del(CNC) | COM | 15135B101 | $322.8M | 9,046,000 | 4.9% |
| Merus N V | COM | N5749R100 | $286.9M | 3,046,916 | 4.4% |
| Viatris Inc(VTRS) | COM | 92556V106 | $238.6M | 24,099,083 | 3.6% |
| United Therapeutics Corp del(UTHR) | COM | 91307C102 | $178.6M | 425,993 | 2.7% |
| Revolution Medicines Inc(RVMD) | COM | 76155X100 | $170.5M | 3,650,342 | 2.6% |
| Indivior PLC(INDV) | ORD | G4766E116 | $168.5M | 6,986,811 | 2.6% |
| Mirum Pharmaceuticals Inc | NOTE 4.000% 5/0 | 604749AB7 | $168.2M | $70,000,000 | 2.6% |
| Neurocrine Biosciences Inc(NBIX) | COM | 64125C109 | $166.3M | 1,184,345 | 2.5% |
| Cogent Biosciences Inc(COGT) | COM | 19240Q201 | $130.0M | 9,053,118 | 2.0% |
| Ionis Pharmaceuticals Inc(IONS) | COM | 462222100 | $129.5M | 1,979,669 | 2.0% |
| Newamsterdam Pharma Company(NAMS) | ORDINARY SHARES | N62509109 | $121.3M | 4,266,693 | 1.9% |
| Vera Therapeutics Inc(VERA) | CL A | 92337R101 | $105.8M | 3,641,157 | 1.6% |
| Bristol-Myers Squibb Co(BMY) | COM | 110122108 | $105.4M | 2,337,771 | 1.6% |
| Adapthealth Corp(AHCO) | COMMON STOCK | 00653Q102 | $102.7M | 11,477,730 | 1.6% |
| Larimar Therapeutics Inc(LRMR) | COM | 517125100 | $98.9M | 30,606,974 | 1.5% |
| Brookdale SR Living Inc(BKD) | COM | 112463104 | $98.6M | 11,641,642 | 1.5% |
| Catalyst Pharmaceuticals Inc(CPRX) | COM | 14888U101 | $98.0M | 4,974,767 | 1.5% |
| Legend Biotech Corp(LEGN) | SPONSORED ADS | 52490G102 | $96.6M | 2,962,338 | 1.5% |
| Biocryst Pharmaceuticals Inc(BCRX) | COM | 09058V103 | $92.4M | 12,169,000 | 1.4% |
| Tandem Diabetes Care Inc | NOTE 1.500% 3/1 | 875372AD6 | $87.1M | $100,000,000 | 1.3% |
| Merck & Co Inc(MRK) | COM | 58933Y105 | $86.4M | 1,030,000 | 1.3% |
| Pfizer Inc(PFE) | COM | 717081103 | $84.2M | 3,303,790 | 1.3% |
| Ionis Pharmaceuticals Inc | NOTE 1.750% 6/1 | 462222AF7 | $82.7M | $60,000,000 | 1.3% |
| Certara Inc(CERT) | COM | 15687V109 | $82.4M | 6,739,537 | 1.3% |
| Inspire MED SYS Inc(INSP) | COM | 457730109 | $77.7M | 1,047,694 | 1.2% |
| ARS Pharmaceuticals Inc(SPRY) | COM | 82835W108 | $75.4M | 7,503,812 | 1.2% |
| Insmed Inc(INSM) | COM PAR $.01 | 457669307 | $67.8M | 471,000 | 1.0% |
| BIO RAD Labs Inc(BIO) | CL A | 090572207 | $63.4M | 226,070 | 1.0% |
| Neogenomics Inc | NOTE 0.250% 1/1 | 64049MAB6 | $62.9M | $72,689,000 | 1.0% |
| Pharvaris N V(PHVS) | COM | N69605108 | $60.9M | 2,442,464 | 0.9% |
| Disc Medicine Inc(IRON) | COM | 254604101 | $60.8M | 919,403 | 0.9% |
| Ideaya Biosciences Inc(IDYA) | COM | 45166A102 | $58.6M | 2,153,043 | 0.9% |
| Bridgebio Oncology Therapeut(BBOT) | COM | 107924102 | $56.6M | 4,885,446 | 0.9% |
| Envista Holdings Corporation(NVST) | COM | 29415F104 | $46.7M | 2,294,036 | 0.7% |
| Praxis Precision Medicines I(PRAX) | COM NEW | 74006W207 | $44.6M | 840,851 | 0.7% |
| Cormedix Inc(CRMD) | COM | 21900C308 | $38.7M | 3,323,833 | 0.6% |
| Enhabit Inc(EHAB) | COM | 29332G102 | $38.0M | 4,747,746 | 0.6% |
| Embecta Corp(EMBC) | COMMON STOCK | 29082K105 | $37.0M | 2,620,421 | 0.6% |
| Livanova PLC | NOTE 2.500% 3/1 | 53802LAB8 | $36.9M | $34,280,000 | 0.6% |
| Celcuity Inc(CELC) | COM | 15102K100 | $36.2M | 733,530 | 0.6% |
| Conmed Corp(CNMD) | COM | 207410101 | $35.8M | 760,196 | 0.5% |
| Zenas Biopharma Inc(ZBIO) | COM | 98937L105 | $34.7M | 1,562,942 | 0.5% |
| Neogenomics Inc(NEO) | COM NEW | 64049M209 | $34.3M | 4,447,331 | 0.5% |
| Arrowhead Pharmaceuticals in(ARWR) | COM | 04280A100 | $34.2M | 993,000 | 0.5% |
| DAY One Biopharmaceuticals I(DAWN) | COM | 23954D109 | $33.2M | 4,705,413 | 0.5% |
| Kymera Therapeutics Inc(KYMR) | COM | 501575104 | $32.4M | 572,258 | 0.5% |
| Caredx Inc(CDNA) | COM | 14167L103 | $31.9M | 2,191,000 | 0.5% |
| Alnylam Pharmaceuticals Inc(ALNY) | COM | 02043Q107 | $31.0M | 67,935 | 0.5% |
| Acadia Healthcare Company in(ACHC) | COM | 00404A109 | $29.4M | 1,189,000 | 0.4% |